Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2024

Description

“Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on methicillin-resistant staphylococcus aureus (mrsa) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for methicillin-resistant staphylococcus aureus (mrsa) drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The methicillin-resistant staphylococcus aureus (mrsa) drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Class: Lipopeptides; Oxazolidinones; Cephalosporin; Tetracycline; Folate Antagonist; Lipoglycopeptide; Other Drug Classes
2) By Indication: Skin Infections; Bone and Joint Infections; Bacteremia; Animal Infections
3) By MRSA Type: Hospital-Acquired (HA-MRSA); Community-Acquired (CA-MRSA)
4) By Route of Administration: Oral Administration; Parenteral Administration
5) By End User: Hospitals and Clinics; Research and Academic Institutes; Other End-Users
Companies Mentioned: Basilea Pharmaceutica Ltd.; Merck & Co Inc.; Pfizer Inc.; Theravance Biopharma Inc.; Allergan plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Methicillin-resistant Staphylococcus aureus (MRSA) drugs encompass a group of medications designed to treat infections caused by the bacterium Staphylococcus aureus that are resistant to methicillin and other commonly used antibiotics. These drugs are specifically selected to target and eliminate MRSA bacteria or hinder their growth. MRSA is a strain of staph bacteria that poses a challenge for treatment due to its resistance to antibiotics.

The main types of methicillin-resistant Staphylococcus aureus (MRSA) drugs include lipopeptides, oxazolidinones, cephalosporins, tetracyclines, folate antagonists, lipoglycopeptides, and others. Lipopeptides are a class of antibiotics containing both lipid and peptide components, and they act by disrupting the bacterial cell membrane, leading to membrane depolarization and inhibition of cell wall synthesis. These drugs find applications in treating various indications such as skin infections, bone and joint infections, bacteremia, and infections in animals. Methicillin-resistant Staphylococcus aureus (MRSA) is categorized into hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA) types. The administration of these drugs can be through oral or parenteral routes and is utilized by various end users, including hospitals, clinics, research and academic institutes, among others.

The methicillin-resistant staphylococcus aureus drugs market research report is one of a series of new reports from The Business Research Company that provides methicillin-resistant staphylococcus aureus drugs market statistics, including methicillin-resistant staphylococcus aureus drugs industry global market size, regional shares, competitors with a methicillin-resistant staphylococcus aureus drugs market share, detailed methicillin-resistant staphylococcus aureus drugs market segments, market trends and opportunities, and any further data you may need to thrive in the methicillin-resistant staphylococcus aureus drugs industry. This methicillin-resistant staphylococcus aureus drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The methicillin-resistant staphylococcus aureus (mrsa) drugs market size has grown strongly in recent years. It will grow from $2.26 billion in 2023 to $2.38 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth observed in the historical period can be attributed to concerns about antibiotic resistance, the prevalence of hospital-acquired infections, increased surgical procedures, a global rise in MRSA cases, and high mortality rates associated with MRSA infections.

The methicillin-resistant staphylococcus aureus (mrsa) drugs market size is expected to see strong growth in the next few years. It will grow to $2.9 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The anticipated growth in the forecast period can be attributed to ongoing challenges related to antibiotic resistance, advancements in MRSA diagnostics, the global prevalence of healthcare-associated infections, increased emphasis on preventive measures in surgery, and the rise in community-acquired MRSA cases. Major trends expected in this forecast period include the exploration of immunomodulators, strategic partnerships for drug development, customized therapies based on strain characteristics, a focus on pediatric-specific formulations, and global health initiatives aimed at combatting antibiotic resistance.

The anticipated rise in the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections is poised to drive the growth of the market for drugs targeting MRSA. MRSA infections result from Staphylococcus bacteria that exhibit resistance to certain antibiotics commonly used to treat standard staph infections. Effective treatment of MRSA infections requires drugs capable of eradicating and inhibiting the growth of MRSA bacteria in both humans and animals. Notably, hospital-acquired MRSA infections witnessed a 14% increase from 2020 to 2021, as reported by the Centers for Disease Control and Prevention in November 2022. Additionally, a December 2022 report by Statens Serum Institute highlighted an increase in community-acquired infections linked to hospital or nursing sector contact in the previous six months. This surge in MRSA prevalence is a driving force behind the growth of the MRSA drug market.

The aging population is expected to contribute to the expansion of the MRSA drugs market. Defined as individuals aged 65 and older, the elderly population is more susceptible to infections, including MRSA, due to compromised immune systems associated with aging. As people age, their immune systems become less effective at defending the body against infections, making bacterial infections such as MRSA more prevalent. According to the World Health Organization's October 2022 report, it is projected that by 2030, one in six people globally will be aged 60 or older. The proportion of the population aged 60 and over will increase from 1 billion in 2020 to 1.4 billion, reaching 2.1 billion by 2050. Consequently, the rise in MRSA infections among the elderly is contributing to the growth of the MRSA drugs market.

A prominent trend in the Methicillin-Resistant Staphylococcus aureus (MRSA) drug market is product innovation. Major companies in this market are actively pursuing innovative products to enhance efficacy and maintain a competitive market position. An example is Melinta Therapeutics LLC, which, in March 2021, announced FDA approval for Kimyrsa (oritavancin), the first one-hour infusion product prepared from a 1,200 mg vial. Kimyrsa is indicated for treating adult patients with acute bacterial skin and skin structure infections caused by susceptible gram-positive microorganisms, including MRSA. The drug acts by inhibiting transpeptidation, transglycosylation, and disrupting cell membrane integrity.

A strategic focus for major companies in the MRSA drug market is conducting clinical trials to improve products and sustain market presence. Clinical trials play a crucial role in researching new treatments and their impact on human health outcomes. For instance, Scope Fluidics S.A., a Poland-based biotechnology company, successfully completed clinical trials in April 2021 for the rapid PCR|ONE genetic test designed to detect the MRSA/MSSA panel. This diagnostic tool is a significant advancement in the quick identification of Staphylococcus aureus infections.

In March 2021, the Biomedical Advanced Research and Development Authority (BARDA) announced a partnership with ContraFect Corporation to develop exebacase, a medication targeting MRSA. This collaboration aims to address secondary bacterial infections that exacerbate sepsis and complicate responses to public health emergencies and standard medical procedures.

Major companies operating in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Basilea Pharmaceutica Ltd., Merck & Co Inc., Pfizer Inc., Theravance Biopharma Inc., Allergan plc, Cumberland Pharmaceuticals Inc., Debiopharm International S.A., The Medicines Company, AbbVie Inc., Innovation Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Absynth Biologics, AmpliPhi Biosciences Corporation, AstraZeneca plc, 3M Co., Meiji Seika Kaisha Ltd., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis, Wockhardt, Sun Pharmaceutical Industries Ltd., Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Astellas Pharma Inc.

North America was the largest region in the global methicillin-resistant staphylococcus aureus drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The methicillin-resistant Staphylococcus aureus (MRSA) drug market consists of sales of vancomycin, daptomycin, linezolid, ceftaroline, tedizolid, and clindamycin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r11911

1. Executive Summary

2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Characteristics

3. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Trends And Strategies

4. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Size and Growth

5.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Segmentation

6.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Lipopeptides
Oxazolidinones
Cephalosporin
Tetracycline
Folate Antagonist
Lipoglycopeptide
Other Drug Classes
6.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Skin Infections
Bone and Joint Infections
Bacteremia
Animal Infections
6.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital-Acquired (HA-MRSA)
Community-Acquired (CA-MRSA)
6.4. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral Administration
Parenteral Administration
6.5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals and Clinics
Research and Academic Institutes
Other End-Users

7. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Regional And Country Analysis

7.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

8.1. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

9.1. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
9.2. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

10.1. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

11.1. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
11.2. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

12.1. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

13.1. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

14.1. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
14.2. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

15.1. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
15.2. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

16.1. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

17.1. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

18.1. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

19.1. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

20.1. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

21.1. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
21.2. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

22.1. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

23.1. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
23.2. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

24.1. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
24.2. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

25.1. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
25.2. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

26.1. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
26.2. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

27.1. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

28.1. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
28.2. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

29.1. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview
29.2. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Landscape And Company Profiles

30.1. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Landscape
30.2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Company Profiles
- 30.2.1. Basilea Pharmaceutica Ltd.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Merck & Co Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Pfizer Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Theravance Biopharma Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Allergan plc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Benchmarking

32. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

34. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Future Outlook and Potential Analysis

34.1 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2028 - Countries Offering Most New Opportunities
34.2 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2028 - Segments Offering Most New Opportunities
34.3 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer